The MedTech Funding Mandate launches on 1 April 2021 and NHS Supply Chain is the agreed supply route for the first four products selected by NHS England and NHS Improvement to be funded in 2021/2022:
- gammaCore – a handheld device which alleviates the symptoms of severe cluster headaches
- HeartFlow – creates a 3D model of a patient’s coronary arteries and assesses the extent and location of blockages
- Placental growth factor based testing – a blood test to rule out pre-eclampsia in pregnant women
- SecurAcath – for securing percutaneous catheters.
On this page you can read an overview of the MedTech Funding Mandate and find out more about the products being funded.
Unfortunately, NHS Supply Chain is unable to advise on commissioning or funding arrangements. For support regarding the implementation of the MedTech Funding Mandate, please contact your local Academic Health Science Network (AHSN) or NHS England and NHS Improvement’s Innovation Team via AAC.firstname.lastname@example.org. See our Useful Links section to find the contact details for your regional AHSN.
About the MedTech Funding Mandate
The NHS Long Term Plan committed to accelerate the uptake of selected innovative medical devices, diagnostics and digital products to patients faster, by developing the MedTech Funding Mandate policy.
The proposal for this policy was consulted on in December 2019 by NHS England and NHS Improvement, with patient representatives, NHS providers, commissioners, charities, academics, delivery partners, consultants, independent health providers and industry. The MedTech Funding Mandate policy received strong support with clear recommendations on the criteria for inclusion technologies.
The MedTech Funding Mandate policy launches on 1 April 2021, having being delayed due to the COVID-19 pandemic.
In 2021/22 the policy will support devices, diagnostics or digital products that:
- are effective: demonstrated through positive NICE guidance
- deliver material savings to the NHS: the benefits of the innovation are over £1 million over five years for the population of England
- are cost-saving in-year: NICE modelling demonstrates a net saving in the first 12 months of implementing the technology
- are affordable to the NHS: the budget impact should not exceed £20 million, in any of the first three years.
The technologies that will be supported by the policy in 2021/22
Expand each of the drop links to find out more about each of the products and how to order them.
gammaCore is a handheld device which provides non-invasive transcutaneous vagus nerve stimulation (nVNS). It is intended for treatment of adults with primary headache, including migraine, cluster headache, and medication overuse headache.
It administers vagus nerve stimulation non-invasively by delivering a mild electrical stimulation through the skin to either the right or the left branches of the vagus nerve in the neck.
gammaCore differs from other vagus nerve stimulators in being applied to the skin of the neck rather than implanted by a surgical procedure.
The device is easy-to-use and patients can carry it with them so that they can use it regularly to prevent cluster headaches or when they feel one coming on.
Vagal Nerve Stimulation Non Implantable Nerve Stimulator 93 day starter kit
Vagal Nerve Stimulation Refill Kit 93 day card and gel only
Vagal Nerve Stimulation Highly conductive multi purpose electrolyte gel
Vagal Nerve Stimulation Refill Kit 31 day card and gel only
Vagal Nerve Stimulation Starter Kit 93 day free of charge
Coronary heart disease (CHD) is the most common type of heart disease and it is estimated that 2.3 million British people currently live with the disease*. Common symptoms of CHD include chest pain or tightness, shortness of breath and heart palpitations. Some patients may have no symptoms.
The HeartFlow Analysis is an advanced test that uses the latest medical imaging technology and data analysis to show how each blockage impacts blood flow to the heart.
It streamlines the diagnostic experience for patients – often eliminating invasive diagnostic procedures for those who do not need them. It also helps ensure those who do need invasive procedures are swiftly and accurately diagnosed. The technology limits redundant non-invasive diagnostic testing, reduces patient time in hospital and face-to-face clinical contact, and helps ensure that hospital visits for those who do need them are streamlined, which is particularly crucial during the COVID-19 pandemic.
The HeartFlow Analysis takes data from a coronary CT angiography (CTA) scan and uses deep learning technology and highly trained analysts to create a personalised, digital 3D model of the patient’s coronary arteries. Its algorithms solve millions of equations to simulate blood flow in a patient’s arteries to help clinicians assess the functional impact of any blockages.
If you have any questions about HeartFlow please contact:
*British Heart Foundation. (2018). CVD Statistics – BHF UK Factsheet https://www.bhf.org.uk.
Placental growth factor (PlGF) tests have been developed to help clinicians and midwives diagnose suspected pre-eclampsia (PE) in pregnant women and to assess the risk for complications associated with PE.
Quidel and Roche Diagnostics are the two suppliers selected under the MedTech Funding Mandate to provide these tests.
Roche Diagnostics – Elecsys sFlt-1/PlGF ratio test: The Elecsys ratio test measures two circulating placentally derived biomarkers; soluble FMS like Tyrosine kinase 1 (sFlt-1) and Placental Growth Factor (PlGF). These biomarkers are detectable in the circulation of pregnant women and their levels are altered in PE; sFlt-1 becomes elevated and PlGF is decreased.
With the Elecsys test, the levels of sFlt-1 and PlGF are measured then converted into a ratio which can predict the women who will not get PE in the following seven days. The Elecsys test can be run on any Roche Elecsys or Cobas e automated analyser in a lab environment.
Quidel Corporation – Quidel Triage PlGF test: The Quidel Triage PlGF test is a quantitative immunoassay for the measurement of PlGF. Circulating maternal PlGF levels are abnormally low in pregnancies with defective placentation and the test is used to help detect abnormal placentation in pregnancies where there is clinical suspicion of preterm PE.
The Quidel Triage PlGF test is run on the Triage MetroPro analyser. It is positioned as either a point-of-care or lab-based test.
Reagent Immunoassay Random Access Systems Elecsys sFlt-1
Reagent Immunoassay Random Access Systems Elecsys PlGF
Reagent Immunoassay Random Access Systems Quidel Triage MeterPro
Reagent Immunoassay Random Access Systems Quidel Triage PLGF Test
Reagent Immunoassay Random Access Systems Quidel Triage PLGF Control 1
Reagent Immunoassay Random Access Systems Quidel Triage PLGF Control 2
SecurAcath is a single-use device to secure percutaneous catheters in position on the skin.
It is intended for use in adults and children who need a central venous catheter (CVC). This is a long, thin, flexible tube that is inserted into a vein through the skin.
It is positioned so that the distal tip lies in a large central vein, usually the superior vena cava, right atrium or inferior vena cava
The benefits of using SecurAcath are:
- One SecurAcath secures for the life of the line
- Dramatically reduces catheter dislodgement and migration
- Catheter remains secure during dressing changes
- Decreases catheter replacement costs
- Reduces catheter related infections and other complications
- Prevents therapy interruption
- Allows easy catheter repositioning if catheter tip must be pulled back
- Improves vessel health and preservation
- Lowers total costs of patient care.
There are two distributors suppling this product:
- Aquilant Ltd
- Infusion Healthcare (Northern Ireland customers only).
Aquilant Ltd products.
Catheter Fixation Device Subcutaneous for PICC 3F
Catheter Fixation Device Subcutaneous for PICC 4F
Catheter Fixation Device Subcutaneous for PICC 5F
Catheter Fixation Device Subcutaneous for PICC and drainage 6F
Catheter Fixation Device Subcutaneous for PICC and drainage 7F
Catheter Fixation Device Subcutaneous for PICC and drainage 8F
Catheter Fixation Device Subcutaneous for PICC and drainage 10F
Catheter Fixation Device Subcutaneous for PICC and drainage 12F
Infusion Healthcare products (Northern Ireland customers only).
|Catalogue Code (NPC)||Product Description|
|FSQ2551||Catheter Fixation Device Subcutaneous for PICC 3F|
|FSQ2552||Catheter Fixation Device Subcutaneous for PICC 4F|
|FSQ2553||Catheter Fixation Device Subcutaneous for PICC 5F|
|FSQ2554||Catheter Fixation Device Subcutaneous for PICC and drainage 6F|
|FSQ2555||Catheter Fixation Device Subcutaneous for PICC and drainage 7F|
|FSQ2556||Catheter Fixation Device Subcutaneous for PICC and drainage 8F|
|FSQ2557||Catheter Fixation Device Subcutaneous for PICC and drainage 10F|
|FSQ2558||Catheter Fixation Device Subcutaneous for PICC and drainage 12F|
How is NHS Supply Chain involved?
NHS Supply Chain is the mandated supply route for these products. Each of the products can be ordered through our Online Catalogue and Ordering system.
If you do not currently purchase products through our route then you will need to be set up with an account. See our Useful Links section for information on how to create an account.
Should you have any patient safety or complaints related to one of the MedTech Funding Mandate products purchased through NHS Supply Chain, please complete our Products Complaints Form.